Ereksiyon Bozukluğu (EB) Tedavisinde İntrakavernozal Trombositten Zengin Plazma Enjeksiyonu
Özet
Ereksiyon bozukluğu (EB), tatminkâr cinsel aktivite için yeterli penis sertliğinin sağlanamaması durumudur ve güncel tedaviler (PDE5İ, enjeksiyonlar, implantlar) genellikle semptomatik olup altta yatan patolojiyi düzeltmez. Bu durum, araştırmacıları rejeneratif ve doku iyileştirici özellikleriyle öne çıkan intrakavernozal trombositten zengin plazma (PRP) tedavisine yöneltmiştir. PRP, hastanın kendi kanından ayrıştırılan yüksek yoğunluktaki büyüme faktörlerini (VEGF, PDGF, FGF, IGF-1) barındırır. Bu faktörler; yeni damar oluşumunu, düz kas hücrelerinin proliferasyonunu ve nöral rejenerasyonu tetikleyerek etki gösterir. Hayvan modellerinde yapılan preklinik çalışmalar, PRP enjeksiyonunun kavernozal sinir hasarı sonrası akson koruması sağladığını ve erektil fonksiyonları belirgin şekilde iyileştirdiğini kanıtlamıştır. Klinik araştırmalar ve meta-analizler ise yöntemin güvenilir, fizibil ve düşük komplikasyon riskine sahip olduğunu, hastaların IIEF-5 skorlarında ve tedavi memnuniyetlerinde anlamlı artışlar sağladığını ortaya koymaktadır. Özellikle sigara içmeyenlerde ve başlangıç IIEF skorları yüksek olan hastalarda tedavi başarısı çok daha belirgindir. İlk çift-kör plasebo kontrollü çalışma da PRP'nin kontrol grubuna kıyasla cinsel işlev üzerinde klinik olarak anlamlı bir iyileşme sunduğunu doğrulamıştır. Sonuç olarak, PRP tek başına veya kombinasyon tedavisi olarak EB fizyopatolojisini geri döndürmede gelecek vadeden, güvenli ve standart tedavi adayı bir modalitedir.
Erectile dysfunction (ED) is characterized by the persistent inability to achieve or maintain a penis erection sufficient for satisfactory sexual performance, and while conventional therapies like PDE5 inhibitors, vacuum devices, and penile implants exist, they offer temporary symptom management rather than correcting the underlying disease pathology. Consequently, intracavernous platelet-rich plasma (PRP) therapy has emerged as a promising restorative alternative due to its tissue-healing properties. Obtained by centrifuging the patient's autologous blood, PRP contains high concentrations of essential growth factors, such as VEGF, PDGF, FGF, and IGF-1, which stimulate angiogenesis, smooth muscle cell proliferation, and neural regeneration. Preclinical animal studies demonstrate that local PRP application effectively preserves myelinated axons and accelerates cavernous nerve recovery after injury, thereby improving erectile function. Furthermore, emerging clinical trials and retrospective analyses substantiate that PRP is a feasible and safe modality with minimal adverse effects, leading to significant increases in patient satisfaction and International Index of Erectile Function (IIEF-5) scores. Notably, predictive factors show that non-smokers and patients with higher baseline scores achieve substantially better therapeutic responses. Recent double-blind, randomized, placebo-controlled trials confirm that PRP provides a clinically significant improvement over saline controls, suggesting its immense potential to become a standard standalone or combination restorative treatment for ED.
Referanslar
Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004 Jul; 1: 6-23.
McCabe MP, Sharlip ID, Lewis R, et al. Incidence and Prevalence of sexual dysfunction in Women and men: a Consensus Statement from the Fourth International Consultation on sexual medicine 2015. J Sex Med 2016 Feb; 13: 144-152
Christensen BS, Gronbaek M, Osler M. Associations between physical and mental health problems and sexual dysfunctions in sexually active Danes. J Sex Med 2011;8:1890-1902.
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol 2018;200:633-641.
Ciocanel O, Power K, Eriksen A. Interventions to treat erectile dysfunction and Premature Ejaculation: an Overview of systematic reviews. Sex Med 2019;7: 251-269.
Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381:153-165.
Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of goal directed therapy for impotence. J Urol 1996;155:1609-1612.
Scott S, Roberts M, Chung E. Platelet-rich plasma and treatment of erectile dysfunction: Critical review of literature and Global Trends in platelet-rich plasma Clinics. Sex Med Rev 2019;7:306-312.
Epifanova MV, Gvasalia BR, Durashov MA, et al. Platelet-rich plasma therapy for male sexual dysfunction: Myth or Reality? Sex Med Rev 2019;8:106-113.
Wu CC, Wu YN, Ho HO, et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med 2012;9:2838-2848. 11. Wu YN, Wu CC, Sheu MT, et al. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med 2016;10:E294-E304.
Ding XG, Li SW, Zheng XM, et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 2009;11:215-221.
Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol 2018;59:61-65.
Epifanova MV, Chalyi ME, Krasnov AO. Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction. Urologiia 2017:46-48.
Zaghloul AS, El-Nashaar AM, Said SZ, Osman IA, Mostafa T. Assessment of the intracavernosal injection platelet-rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non-responding to on-demand oral PDE5 inhibitors. Andrologia. 2022 Mar 17:e14421. doi: 10.1111/and.14421. Epub ahead of print. PMID: 35301742.
Alkandari MH, Touma N, Carrier S. Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence. Sex Med Rev. 2022 Apr;10(2):341-352. doi: 10.1016/j.sxmr.2020.12.004. Epub 2021 Jul 2. PMID: 34219010.
Geyik S. Comparison of the efficacy of low-intensity shock wave therapy and its combination with platelet-rich plasma in patients with erectile dysfunction. Andrologia. 2021 Nov;53(10):e14197. doi: 10.1111/and.14197. Epub 2021 Aug 4. PMID: 34350629.
Taş T, Çakıroğlu B, Arda E, Onuk Ö, Nuhoğlu B. Early Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunction. Sex Med. 2021 Apr;9(2):100313. doi: 10.1016/j.esxm.2020.100313. Epub 2021 Jan 30. PMID: 33529814; PMCID: PMC8072172.
Britt D, Blankstein U, Lenardis M, Millman A, Grober E, Krakowsky Y. Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data. Can Urol Assoc J. 2021 Jun;15(6):202-206. doi: 10.5489/cuaj.6947. PMID: 33212009; PMCID: PMC8195577.
Liu JL, Chu KY, Gabrielson AT, Wang R, Trost L, Broderick G, Davies K, Brock G, Mulhall J, Ramasamy R, Bivalacqua TJ. Restorative Therapies for Erectile Dysfunction: Position Statement From the Sexual Medicine Society of North America (SMSNA). Sex Med. 2021 Jun;9(3):100343. doi: 10.1016/j.esxm.2021.100343. Epub 2021 May 14. PMID: 34000480; PMCID: PMC8240368.
Zaghloul AS, Mahmoud ElNashar AER, GamalEl Din SF, Zaki Said S, Saad HM, Refaat Eldebs H, Abdel Latif Osman I. Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet-rich plasma in patients with erectile dysfunction: A prospective pilot study. Andrologia. 2021 Oct;53(9):e14162. doi: 10.1111/and.14162. Epub 2021 Jun 30. PMID: 34196015.
Poulios E, Mykoniatis I, Pyrgidis N, Zilotis F, Kapoteli P, Kotsiris D, Kalyvianakis D, Hatzichristou D. Platelet-Rich Plasma (PRP) Improves Erectile Function: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. J Sex Med. 2021 May;18(5):926-935. doi: 10.1016/j.jsxm.2021.03.008. Epub 2021 Apr 24. PMID: 33906807.
